Oligodendrogliomas Completed Phase 2 Trials for Temozolomide (DB00853)

Back to Oligodendrogliomas

Also known as: Oligodendroglioma of Brain / Oligodendroglioma / Oligodendroglioma - category (morphologic abnormality) / Oligodendroglioma (morphologic abnormality) / [M]Oligodendroglioma NOS (morphologic abnormality)

IndicationStatusPhase
DBCOND0032978 (Oligodendrogliomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00575887Efficacy of Protracted Temozolomide in Patients With Progressive High Grade GliomaTreatment
NCT00392171The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)Treatment
NCT00165360Prolonged Daily Temozolomide for Low-Grade GliomaTreatment